A phase II study to evaluate efficacy and safety of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancer
- Conditions
- non-squamous non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000009476
- Lead Sponsor
- The Tokyo cooperative oncology group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 39
Not provided
1.Symptomatic brain metastases 2.history of active double cancer within 5 years 3.Current history of hemosputum or hemoptysis 4.Have possibly complication related to bleeding episode 5.Receiving anticoagulant drug (including Aspirin over 325mg/day) 6.Great vessel involvement 7.Have received radiation therapy to lesions of lung 8.Pleural effusion,peritoneal fluid, and pericardial fluid 9.Serious complications 10.Perforation of the digestive tract or history of the perforation of the digestive tract within the past one year 11.Uncontrollable Hypertension 12.Interstitial pneumonia or pulmonary fibrosis detectable on X ray 13.Proven or suspected infections diseases 14.Watery diarrhea or Chronic constipation 15.Under treatment by flucytosine 16.Hypersensitivity of Protocol agents 17.History of pregnancy or lactation and no intention to practice birth control 18.Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method